Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria.
Takahashi K, Nakamura A, Furusawa S, Yokozeki K, Sugawara H, Yanagisawa H, Akikawa K, Kikuchi H. Takahashi K, et al. Among authors: furusawa s. J Clin Transl Endocrinol. 2020 Nov 25;22:100244. doi: 10.1016/j.jcte.2020.100244. eCollection 2020 Dec. J Clin Transl Endocrinol. 2020. PMID: 33318949 Free PMC article.
Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
Nomoto H, Furusawa S, Nakamura A, Takeuchi J, Nagai S, Yokoyama H, Sakuma I, Taneda S, Kurihara Y, Aoki S, Miya A, Kameda H, Cho KY, Atsumi T, Miyoshi H. Nomoto H, et al. Among authors: furusawa s. BMJ Open. 2022 May 18;12(5):e056885. doi: 10.1136/bmjopen-2021-056885. BMJ Open. 2022. PMID: 35584872 Free PMC article.
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S, Nomoto H, Yokoyama H, Suzuki Y, Tsuzuki A, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Taneda S, Kurihara Y, Nakamura A, Atsumi T; SWITCH-SEMA 2 study group. Furusawa S, et al. Diabetes Obes Metab. 2024 Mar;26(3):961-970. doi: 10.1111/dom.15393. Epub 2023 Dec 11. Diabetes Obes Metab. 2024. PMID: 38073422 Clinical Trial.
Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
Nomoto H, Furusawa S, Yokoyama H, Suzuki Y, Izumihara R, Oe Y, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Kurihara Y, Nakamura A, Atsumi T. Nomoto H, et al. Among authors: furusawa s. J Clin Endocrinol Metab. 2024 May 2:dgae213. doi: 10.1210/clinem/dgae213. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 38695547
Physical mechanism of core-collapse supernovae that neutrinos drive.
Yamada S, Nagakura H, Akaho R, Harada A, Furusawa S, Iwakami W, Okawa H, Matsufuru H, Sumiyoshi K. Yamada S, et al. Among authors: furusawa s. Proc Jpn Acad Ser B Phys Biol Sci. 2024;100(3):190-233. doi: 10.2183/pjab.100.015. Proc Jpn Acad Ser B Phys Biol Sci. 2024. PMID: 38462501 Free PMC article. Review.
Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A.
Ishimaru K, Ikeda M, Miyamoto HD, Furusawa S, Abe K, Watanabe M, Kanamura T, Fujita S, Nishimura R, Toyohara T, Matsushima S, Koumura T, Yamada KI, Imai H, Tsutsui H, Ide T. Ishimaru K, et al. Among authors: furusawa s. J Am Heart Assoc. 2024 Jan 2;13(1):e031219. doi: 10.1161/JAHA.123.031219. Epub 2023 Dec 29. J Am Heart Assoc. 2024. PMID: 38158218 Free PMC article.
363 results